Biomarker discovery for renal cancer stem cells
C Corro, H Moch - The Journal of Pathology: Clinical Research, 2018 - Wiley Online Library
Characterised by high intra‐and inter‐tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
Biomarker discovery for renal cancer stem cells
C Corrò, H Moch - The journal of pathology. Clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Characterised by high intra-and inter-tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo-and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo-and radiotherapy. Therefore, the development of new …
[HTML][HTML] Biomarker discovery for renal cancer stem cells
C Corrò, H Moch - The Journal of Pathology: Clinical Research, 2018 - ncbi.nlm.nih.gov
Characterised by high intra‐and inter‐tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
Biomarker discovery for renal cancer stem cells.
C Corrò, H Moch - The journal of pathology. Clinical research, 2018 - sonar.ch
English Characterised by high intra-and inter-tumor heterogeneity, metastatic renal cell
carcinoma (RCC) is resistant to chemo-and radiotherapy. Therefore, the development of …
carcinoma (RCC) is resistant to chemo-and radiotherapy. Therefore, the development of …
Biomarker discovery for renal cancer stem cells
C Corrò, H Moch - The Journal of Pathology: Clinical Research, 2018 - search.proquest.com
Characterised by high intra‐and inter‐tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
Biomarker discovery for renal cancer stem cells.
C Corrò, H Moch - The Journal of pathology. Clinical Research, 2018 - europepmc.org
Characterised by high intra‐and inter‐tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
Biomarker discovery for renal cancer stem cells.
C Corrò, H Moch - The journal of pathology. Clinical research, 2018 - folia.unifr.ch
English Characterised by high intra-and inter-tumor heterogeneity, metastatic renal cell
carcinoma (RCC) is resistant to chemo-and radiotherapy. Therefore, the development of …
carcinoma (RCC) is resistant to chemo-and radiotherapy. Therefore, the development of …
Biomarker discovery for renal cancer stem cells
C Corrò, H Moch - The Journal of Pathology: Clinical Research, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Characterised by high intra‐and inter‐tumor
heterogeneity, metastatic renal cell carcinoma (RCC) is resistant to chemo‐and …
heterogeneity, metastatic renal cell carcinoma (RCC) is resistant to chemo‐and …
Biomarker discovery for renal cancer stem cells.
C Corrò, H Moch - The Journal of pathology. Clinical Research, 2018 - europepmc.org
Characterised by high intra‐and inter‐tumor heterogeneity, metastatic renal cell carcinoma
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …
(RCC) is resistant to chemo‐and radiotherapy. Therefore, the development of new …